Clinical Development Services
Myosin Inhibitors’ Central Role in the Future of Hypertrophic Cardiomyopathy
Camzyos is the first myosin inhibitor that targets the underlying pathophysiology of hypertrophic cardiomyopathy.
Camzyos is the first myosin inhibitor that targets the underlying pathophysiology of hypertrophic cardiomyopathy.